All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

External monitors press pause on KEYNOTE phase III clinical trials of pembrolizumab

By Fiona Chaplin

Share:

Jun 13, 2017


Much emphasis has been put on immune checkpoint inhibitors as the rising stars in targeted therapy for Multiple Myeloma (MM). Pembrolizumab is one such inhibitor targeting the programmed cell death receptor (PD-1) on lymphocytes, and was a major player in Merck’s portfolio, showing promising results in initial combination trials.

Yesterday an external data monitoring committee put the brakes on two phase III trials, KEYNOTE-183 and KEYNOTE-185, designed to assess the efficacy of pembrolizumab with pomalidomide and low-dose dexamethasone, and lenalidomide and low-dose dexamethasone, respectively. KEYNOTE-183 had enrolled heavily pre-treated MM patients that had received a minimum of two lines of prior treatment and were ineligible for transplant, whereas KEYNOTE-185 had enrolled patients with newly diagnosed MM who were treatment naive.

Patients currently enrolled in the trials will continue as planned, but researchers are no longer allowed to recruit new patients while an investigation is carried out. This decision was taken as a consequence of a higher than expected number of deaths. This will be a big setback for Merck, as a planned expansion of the treatment indication for pembrolizumab into MM would have been resting on these trials. Pembrolizumb is currently approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of a number of other cancers, such as melanoma, advanced non-small lung cancer and Hodgkin’s Lymphoma; and by the FDA for the treatment of bladder cancer.

References

Your opinion matters

Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?